Sanofi abandons licensing deal for Maze drug following US FTC challenge
Sanofi and Maze Therapeutics have abandoned a proposed licensing agreement for Maze’s MZE001 Pompe disease therapy after the US Federal Trade Commission filed a complaint to block the deal.Sanofi and Maze...To view the full article, register now.
Already a subscriber? Click here to view full article